Comparative Pharmacology
Head-to-head clinical analysis: FLAXEDIL versus SYNCURINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAXEDIL versus SYNCURINE.
FLAXEDIL vs SYNCURINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLAXEDIL (gallamine triethiodide) is a nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at nicotinic receptors at the neuromuscular junction, preventing muscle contraction.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking neurotransmission and causing skeletal muscle paralysis.
0.08-0.12 mg/kg IV bolus for neuromuscular blockade; additional doses of 0.01-0.02 mg/kg as needed.
0.1-0.2 mg/kg IV bolus for paralysis, repeat 0.05-0.1 mg/kg as needed; maintenance infusion 0.5-1.5 mcg/kg/min IV.
None Documented
None Documented
The terminal elimination half-life of gallamine is approximately 2-4 hours in patients with normal renal function. This half-life is inversely related to creatinine clearance, and may be prolonged to 12-24 hours or more in patients with renal impairment, leading to cumulative effects and prolonged neuromuscular blockade.
Terminal half-life: 2-5 hours (prolonged with renal impairment; up to 10 hours in severe impairment)
Flaxedil (gallamine triethiodide) is excreted primarily unchanged by the kidneys via glomerular filtration. Approximately 90-95% of an administered dose is eliminated in urine within 24 hours, with the remainder excreted in feces (<5%) via biliary elimination.
Primarily renal excretion (50-70% unchanged drug), with biliary/fecal elimination (10-20%)
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent